You are here
Thursday, September 9, 2010
NIH statement on National HIV/AIDS and Aging Awareness Day Sept. 18, 2010
From Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases Richard J. Hodes, M.D., Director, National Institute on Aging Jack Whitescarver, Ph.D., Director, NIH Office of AIDS Research.
Older HIV-infected adults face unique health challenges stemming from age-related changes to the body accelerated by HIV infection, the side effects of long-term treatment for HIV, the infection itself and often, treatments for age-associated illnesses. Sept. 18 marks the third annual National HIV/AIDS and Aging Awareness Day, an opportunity to highlight these challenges and the research under way to improve the health and quality of life of older people infected with HIV.
Many HIV-infected individuals are living into their 50s and well beyond as a result of the powerful combinations of antiretroviral drugs that suppress the replication of the virus. In 2006, an estimated 25 percent of people living with HIV in the United States were age 50 years and older. In those with long-term HIV infection, the persistent activation of immune cells by the virus likely increases the susceptibility of these individuals to inflammation-induced diseases and diminishes their capacity to fight certain diseases. Coupled with the aging process, the extended exposure of these adults to both HIV and antiretroviral drugs appears to increase their risk of illness and death from cardiovascular, bone, kidney, liver and lung disease, as well as many cancers not associated directly with HIV infection.
In addition, a growing number of adults in their 40s and 50s with long-term HIV infection are experiencing syndromes that resemble premature aging. For instance, these individuals have a greater risk of impaired kidney function and end-stage renal disease than their HIV-uninfected counterparts. They also are three to four times more likely to develop osteoporosis, increasing their risk for bone fractures. In addition, 55-year-old HIV-infected men are as likely to be in frail condition as are men ages 65 years or older who do not have HIV.
In 2008, an estimated 16 percent of all new HIV diagnoses occurred in people ages 50 years and older in the 37 states with confidential name-based reporting. HIV disease progresses more quickly in older compared with younger adults, and antiretroviral therapy restores immune system cells less effectively, placing this older group at greater risk for illness and death from HIV infection than younger people who are infected for comparable periods of time. Moreover, the higher rate of pre-existing conditions in people of advanced age often complicates their treatment for HIV infection.
Older people and their health care providers may not consider individuals ages 50 years and over to be at risk for HIV infection, and consequently may not discuss or act on HIV prevention measures. To complicate matters, the signs and symptoms of AIDS in older adults can be mistaken for conditions associated with aging, delaying the diagnosis of HIV infection and the start of appropriate therapy. In the United States, nearly one-fifth of the individuals ages 55 years and older who were living with HIV in 2006 did not know they were infected. As a consequence of both late HIV diagnosis and greater risk of progressing to AIDS, adults ages 50 years and older are more likely than any other age group to be diagnosed with AIDS within a year of their HIV diagnosis, according to data gathered between 1996 and 2005.
To counteract these trends, health care providers should routinely discuss risk factors for HIV infection with older patients, educate them about HIV prevention measures and offer HIV testing. Because early HIV diagnosis is key to optimal treatment, the Centers for Disease Control and Prevention recommends routine HIV testing for all adults up to age 64 years. CDC also recommends HIV testing for adults ages 64 years and over who have risk factors for HIV infection, such as multiple sexual partners, unprotected sex or injection drug use. Medicare covers HIV screening once every 12 months for any Medicare participant who asks for the test.
NIH is funding a variety of studies to address the challenges posed by HIV, including aging and the effects of long-term treatment with antiretroviral drugs. Study topics range from HIV-induced decline of immune system function to the increased risk of cardiovascular disease, from the effect of menopause-induced hormonal changes on HIV-infected women to the early detection of kidney disease, and from the decline of memory and cognition in long-term HIV infection to the greater risk of osteoporosis and bone fractures.
Some of these studies are being funded through an ongoing grant program called Medical Management of Older Patients with HIV/AIDS, established by the National Institute of Allergy and Infectious Diseases, the National Institute on Aging, the National Institute of Mental Health and the National Institute of Nursing Research, all part of NIH. This program continues to solicit research proposals to study a range of biomedical issues relevant to older adults with HIV infection. More information is available at http://grants.nih.gov/grants/guide/pa-files/PA-09-018.html, http://grants.nih.gov/grants/guide/pa-files/PA-09-019.html, and http://grants.nih.gov/grants/guide/pa-files/PA-09-017.html.
HIV clearly poses a risk to individuals 50 years and older and presents complex treatment challenges. Therefore, older adults at risk need to get tested for the virus and take steps to protect themselves and their loved ones from becoming infected. In addition, NIH-funded research is under way to help health care providers tackle the often complicated treatment of HIV infection and related illnesses in older individuals, as well as the phenomenon of accelerated aging due to long-term HIV infection. While NIH continues to seek a cure for HIV infection and to develop more varied and powerful HIV prevention tools, we remain committed to helping HIV-infected adults live longer, healthier lives.
Dr. Fauci is director of the National Institute of Allergy and Infectious Diseases; Dr. Hodes is director of the National Institute on Aging; and Dr. Whitescarver is director of the Office of AIDS Research, all at the National Institutes of Health in Bethesda, Maryland.
More information on HIV and aging is available at AIDS.gov (http://www.aids.gov/hiv-aids-basics/diagnosed-with-hiv-aids/overview/aging-population/).
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
The Office of AIDS Research (OAR), a part of the Office of the Director of NIH, plans and coordinates the scientific, budgetary and policy elements of the NIH AIDS program. Information about the OAR and NIH AIDS research can be found at http://www.oar.nih.gov/.
The NIA leads the federal effort supporting and conducting research on aging and the medical, social and behavioral issues of older people. For more information on research and the aging, go to www.nia.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®
1. Centers for Disease Control and Prevention (CDC). 2008. HIV prevalence estimates—United States, 2006. MMWR 57(39):1074. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5739a2.htm.
2. Eggers PW et al. 2004. Is there an epidemic of HIV infection in the US ESRD program? Journal of the American Society of Nephrology 15(9):2477-2485. 3. Brown TT et al. 2006 Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20(17):2165-2174.
4. Desquilbet L et al. 2007 HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. Journal of Gerontology: Biological Sciences 62(11):1279-1286.
5. CDC. 2010. HIV Surveillance Report, 2008. Table 1a. Accessed August 10, 2010. Available at http://www.cdc.gov/hiv/surveillance/resources/reports/2008report/table1a.htm.
6. Campsmith ML et al. 2010. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. Journal of Acquired Immune Deficiency Syndrome 53(5):621.
7. CDC. 2009. Late HIV testing — 34 states, 1996-2005. MMWR 58(24):664. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5824a2.htm.